18529-12-9

Usage

Uses

Used in Pharmaceutical Industry:
2-CHLORO-6-FLUORO-4-METHYLQUINOLINE is used as a pharmaceutical agent for its antimicrobial and antimalarial properties, making it a promising candidate for the development of new drugs to combat resistant infections and malaria.
Used in Drug Synthesis:
As a quinoline derivative, 2-CHLORO-6-FLUORO-4-METHYLQUINOLINE is used as a building block in the synthesis of various pharmaceutical agents and bioactive molecules, contributing to the discovery and development of novel therapeutics.
Used in Agrochemical Production:
2-CHLORO-6-FLUORO-4-METHYLQUINOLINE is used as an intermediate in the production of agrochemicals, playing a role in the development of new pesticides and other specialty chemicals for agricultural applications.

InChI:InChI=1/C10H7ClFN/c1-6-4-10(11)13-9-3-2-7(12)5-8(6)9/h2-5H,1H3

Upstream product

• 15912-69-3 6-fluoro-2-hydroxy-4-methylquinoline 
• 2713-85-1 N-(4-fluorophenyl)-3-oxobutanamide 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 108099-80-5 6-fluoro-2-hydrazino-4-methylquinoline 
• 109274-62-6 [1-(6-Fluoro-4-methyl-quinolin-2-yl)-3,5-dimethyl-1H-pyrazol-4-yl]-acetic acid 

Relevant academic research and scientific papers

Compounds having anticonvulsion activity, preparing methods thereof and applications of the compounds

The invention provides 7-substituted-5-methyl-1,2,4-triazolo[4,3-a] quinoline and 7-substituted-5-ethoxy-[1,2,4]-triazolo[4,3-a] quinoline compounds having anticonvulsion activity, preparing methods thereof and applications of the compounds in the field of preparing anticonvulsion medicines.

Novel aryl- and heteroarylpiperazines

Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.

Anti-mutagenic structural modification by fluorine-substitution in highly mutagenic 4-methylquinoline derivatives

We have previously shown that fluorine-substitution at position 3 of quinoline deprived this molecule of mutagenicity, possibly due to interference with the yield of its metabolically activated form, the 1,4-hydrated 2,3-epoxide (enamine epoxide), which is directly responsible for the mutagenic modification of DNA. To further explore the possibility of a method for anti-mutagenic modification of mutagens by fluorine-substitution, 4-methylquinoline (4-MeQ), the most mutagenic form of all the quinoline derivatives examined so far, was used as a target in the present study. Five mono- and di-fluorinated derivatives of 4-MeQ, 2-fluoro-4-methylquinoline (2-F-4-MeQ), 6-F-4-MeQ, 7-F-4-MeQ, 2,6-difluoro-4-methylquinoline (2,6-diF-4-MeQ), and 2,7-diF-4-MeQ, were subjected to analysis of their structure-mutagenicity relationships. The 2-fluorinated derivatives (2-F-4-MeQ, 2,6-diF-4-MeQ, and 2,7-diF-4-MeQ) were all non-mutagenic in the Ames test. 7-F-4-MeQ was as highly mutagenic as, and 6-F-4-MeQ was less mutagenic than non-fluorinated 4-MeQ. Metabolic studies were also conducted with 4-MeQ, 2-F-4-MeQ, 6-F-4-MeQ, and 7-F-4-MeQ, using a liver microsomal enzyme fraction prepared from the 3-methylcholanthrene-treated rat. The HPLC analytical data showed that, although the metabolic patterns (hydroxylation at 4-methyl group as a main metabolic pathway and 3-hydroxylation as a minor pathway) of these four F-MeQs were similar to one another, only the 3-hydroxy metabolite of 2-F-4-MeQ was not produced under the present experimental conditions employed. These results suggest that fluorine-substitution at position 2 of 4-MeQ inhibited the formation of the enamine epoxide in the pyridine moiety and deprived this molecule of mutagenicity as in the case of quinoline. Copyright (C) 2000 Elsevier Science B.V.